Methods for the synthesis of arginine-containing peptides are provided. The methods include a deprotection step that minimizes the transfer of by-products deriving from cleaved sulfonyl-5 based side chain protecting groups from arginine to amino acids carrying electron rich side chains.

There is provided a range of novel disulfide bond containing compounds. These disulfide bond containing compounds can be used in a variety of applications such as solid phase peptide synthesis, solid phase organic synthesis, formation of dendrimers, formation of macromolecules and formation cyclic peptides; and as a component of a delivery vehicle with a bioactive molecule.

The invention provides a method for reducing oxidative damage in a mammal, a removed organ, or a cell in need thereof. The method comprises administering an effective amount of an aromatic cationic peptide. The aromatic cationic peptide has (a) at least one net positive charge; (b) a minimum of three amino acids; (c) a maximum of about twenty amino acids, (d) a relationship between the minimum number of net positive charges (p.sub.m) and the total number of amino acid residues (r) wherein 3 p.sub.m is the largest number that is less than or equal to r+1; (e) a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (p.sub.t) wherein 3a or 2a is the largest number that is less than or equal to p.sub.t+1, except that when a is 1, p.sub.t may also be 1; and (f) at least one tyrosine or tryptophan amino acid.

The present disclosure relates to a cell-laden microgel comprising self-assembly ultrashort peptide (SUP) and a method of frabricating such cell-laden microgels. The present disclosure also relates to a cell microcarrier comprising cell-laden microgels, which is suitable for medical applications such as cell therapy. The present disclosure further relates to a system comprising a combination of SUP microgel and SUP bulk hydrogel for vascularized tissue culture and a method of creating such a vascularized 3D tissue constructs with improved cell viability and proliferation.

The enclosed disclosure describes, among other things, a method including the steps of a first deaerating step in which a mixture comprising peptides is deaerated by lowering the pressure, filtering the mixture through a sterilizing filter; and a second deaerating step, in which the filtrate is deaerated by vibration and lowering the pressure.

Provided is a cell culture scaffold material having excellent extensibility of pseudopodia and excellent cell proliferation. The cell culture scaffold material according to the present invention contains a peptide-conjugated polyvinyl alcohol derivative having a polyvinyl alcohol derivative portion and a peptide portion, and has a hydroxyl value of 1,100 mgKOH/g or less.

The invention provides a method for treating one or more complications of diabetes in a mammal. The method comprises administering to a mammal in need thereof an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (p.sub.m) and the total number of amino acid residues (r) wherein 3 p.sub.m is the largest number that is less than or equal to r+1; and a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (p.sub.t) wherein 2a is the largest number that is less than or equal to p.sub.t+1, except that when a is 1, p.sub.t may also be 1.

The enclosed disclosure describes, among other things, a method including the steps of a first deaerating step in which a mixture comprising peptides is deaerated by lowering the pressure, filtering the mixture through a sterilizing filter; and a second deaerating step, in which the filtrate is deaerated by vibration and lowering the pressure.

The present invention relates to SS-31 or composition comprising SS-31 for use in the treatment and/or prevention of aneurysm.

Disclosed herein are transfection complexes comprising at least one cell surface ligand; at least one helper lipid component; and a transfection enhancer. Also disclosed are pharmaceutical compositions comprising the disclosed transfection complexes, and a pharmaceutically acceptable carrier. Further, disclosed are methods of transfecting a cell, the method comprising the steps of: obtaining a transfection complex as disclosed; and contacting a cell with the transfection complex.